Stockscreener 앱 받기
2.16
2.86%
0.06
시간 외 거래:
2.12
-0.04
-1.85%
전일 마감가:
$2.10
열려 있는:
$2.1
하루 거래량:
1.94M
Relative Volume:
1.33
시가총액:
$214.23M
수익:
$11.16M
순이익/손실:
$-148.13M
주가수익비율:
-1.3598
EPS:
-1.5885
순현금흐름:
$-112.35M
1주 성능:
+9.64%
1개월 성능:
+1.41%
6개월 성능:
+14.89%
1년 성능:
+111.76%
1일 변동 폭
$2.085
$2.2497
1주일 범위
$1.88
$2.2497
52주 변동 폭
$0.9573
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
명칭
Caribou Biosciences Inc
전화
510-982-6030
주소
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.16 | 208.28M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-08 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-10-31 | 개시 | Evercore ISI | Outperform |
| 2023-07-11 | 개시 | Truist | Buy |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-11-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-17 | 개시 | BofA Securities | Buy |
| 2021-08-17 | 개시 | Citigroup | Neutral |
| 2021-08-17 | 개시 | SVB Leerink | Outperform |
모두보기
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $11 - Moomoo
CRBU SEC FilingsCaribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CRBU: Allogeneic CAR T programs show strong clinical progress and are advancing toward pivotal trials - TradingView
Caribou Biosciences stock (US1420381089): Q1 update and CRISPR pipeline stay in focus - AD HOC NEWS
CRBU Technical Analysis & Stock Price Forecast - Intellectia AI
Caribou Biosciences brings CMO and CFO to BioConnect Investor Conference fireside chat - Traders Union
CRBU Technical Analysis | Trend, Signals & Chart Patterns | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Caribou Biosciences stock (US1420381089): fresh data from latest CAR?T update keeps investors watchi - AD HOC NEWS
Transcript : Caribou Biosciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 08 - marketscreener.com
Caribou Biosciences (CRBU) price target increased by 38.57% to 12.37 - MSN
Caribou Biosciences stock (US1420381089): Q1 earnings beat and 4.4% surge - AD HOC NEWS
May 2026's Promising Penny Stocks - Yahoo Finance
Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU) - The Globe and Mail
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference - The Manila Times
Caribou Biosciences attends BioConnect Investor Conference in New York next week - Traders Union
CRISPR biotech Caribou Biosciences plans H.C. Wainwright talk May 19 - Stock Titan
Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues - simplywall.st
Industry Analysts Just Upgraded Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts By 30% - Moomoo
Industry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts - Yahoo Finance
EHA2026 spotlights Caribou Biosciences advances in allogeneic CAR-T treatments for lymphoma and multiple myeloma - Traders Union
Caribou Biosciences, Inc. Announces Acceptance of Two Oral Presentations at the 2026 European Hematology Association Annual Meeting - Quiver Quantitative
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Caribou Biosciences CEO Rachel Haurwitz to join Bank of America conference fireside chat - Traders Union
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Q4 EPS Forecast for Caribou Biosciences Lowered by Analyst - MarketBeat
MSN Money - MSN
Caribou Biosciences (NASDAQ:CRBU) Issues Quarterly Earnings Results - MarketBeat
Caribou Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Caribou Biosciences 報告了2026年第一季度的財務業績並提供了業務更新。 - Moomoo
RBC Capital Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $10 - Moomoo
BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Caribou Biosciences, Inc. (CRBU) reports Q1 loss, misses revenue estimates - MSN
Caribou Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Caribou Biosciences (NASDAQ: CRBU) trims Q1 2026 loss, holds $118.6M cash - Stock Titan
Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Caribou secures FDA alignment on phase 3 trial, sees cash into 2H 2027 - Stock Titan
Caribou Biosciences (NASDAQ: CRBU) trims Q1 loss, holds $118.6M cash - Stock Titan
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference - The Manila Times
Caribou Biosciences to participate in BofA Securities Health Care event in Las Vegas - Traders Union
Caribou Biosciences (CRBU) price target decreased by 22.79% to 8.92 - MSN
Caribou Biosciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Caribou Biosciences (CRBU) corrects record‑date shares, June 17 virtual annual meeting - Stock Titan
Caribou Biosciences Inc (CRBU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):